ProKidney (PROK) News Today $2.33 -0.04 (-1.69%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 6 at 4:21 AM | americanbankingnews.comProKidney (NASDAQ:PROK) PT Lowered to $3.00September 5 at 4:48 PM | markets.businessinsider.comMaintaining Hold on ProKidney Amid Strategic Shifts and Regulatory UncertaintiesSeptember 5 at 4:48 PM | markets.businessinsider.comProKidney’s Hold Rating Maintained Amid Financing and Clinical UncertaintiesSeptember 5 at 4:48 PM | finance.yahoo.comProKidney drops Phase III CKD study to focus on US market and save up to $175mSeptember 5 at 4:23 PM | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 6%ProKidney (NASDAQ:PROK) Shares Up 6%September 5 at 1:13 AM | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Down on Analyst DowngradeSeptember 4 at 10:29 AM | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Down After Analyst DowngradeProKidney (NASDAQ:PROK) Shares Gap Down Following Analyst DowngradeSeptember 4 at 9:27 AM | marketbeat.comBank of America Trims ProKidney (NASDAQ:PROK) Target Price to $3.00Bank of America dropped their price target on shares of ProKidney from $4.00 to $3.00 and set a "neutral" rating for the company in a research note on Wednesday.September 4 at 6:19 AM | markets.businessinsider.comProKidney Reports Strategic Updates To Phase 3 Study Of Rilparencel; To Discontinue PROACT 2 StudySeptember 3, 2024 | msn.comProKidney revises Phase 3 program for lead assetSeptember 3, 2024 | globenewswire.comProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel's Registrational Path to Potential Approval in the U.S.August 31, 2024 | americanbankingnews.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.21August 27, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Down 5.9%ProKidney (NASDAQ:PROK) Trading Down 5.9%August 27, 2024 | globenewswire.comProKidney to Participate in the Morgan Stanley 22nd Annual Global Healthcare ConferenceAugust 23, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Up 8.3%ProKidney (NASDAQ:PROK) Trading 8.3% HigherAugust 23, 2024 | seekingalpha.comThe Prognosis For ProKidney: UnclearAugust 19, 2024 | marketbeat.comVanguard Group Inc. Sells 1,085,965 Shares of ProKidney Corp. (NASDAQ:PROK)Vanguard Group Inc. reduced its holdings in ProKidney Corp. (NASDAQ:PROK - Free Report) by 37.5% during the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 1,813,079 shares of the company's stock after selling 1,085,965 shares durAugust 16, 2024 | bizjournals.comProKidney resumes manufacturing and Phase 3 clinicals, extends cash runwayAugust 12, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.18ProKidney (NASDAQ:PROK) Shares Gap Up to $2.18August 9, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 6.2% Higher ProKidney (NASDAQ:PROK) Stock Price Up 6.2%August 9, 2024 | globenewswire.comProKidney Reports Business Updates and Second Quarter 2024 Financial ResultsJuly 30, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Down 5.5%ProKidney (NASDAQ:PROK) Shares Down 5.5%July 30, 2024 | finance.yahoo.comProKidney Corp.'s (NASDAQ:PROK) top owners are retail investors with 32% stake, while 30% is held by institutionsJuly 25, 2024 | finance.yahoo.comChronic Kidney Disease for Seven Major Markets: US, France, Germany, Italy, Spain, UK, Japan Drug Forecasts and Analysis 2023-2033July 23, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 7.9% Higher ProKidney (NASDAQ:PROK) Trading Up 7.9%July 16, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 3.8% ProKidney (NASDAQ:PROK) Trading Down 3.8%July 9, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading 8.1% Higher ProKidney (NASDAQ:PROK) Trading Up 8.1%July 2, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Down 3.2%ProKidney (NASDAQ:PROK) Trading Down 3.2%June 27, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Up 7%ProKidney (NASDAQ:PROK) Stock Price Up 7%June 27, 2024 | investorplace.comPROK Stock Earnings: ProKidney Reported Results for Q4 2023June 26, 2024 | insidertrades.comInsider Buying: ProKidney Corp. (NASDAQ:PROK) Insider Acquires 8,264,462 Shares of StockJune 25, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Up to $2.31ProKidney (NASDAQ:PROK) Shares Gap Up to $2.31June 20, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Stock Price Down 8.2%ProKidney (NASDAQ:PROK) Shares Down 8.2%June 17, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Gap Up on Insider Buying ActivityProKidney (NASDAQ:PROK) Shares Gap Up on Insider Buying ActivityJune 15, 2024 | insidertrades.comProKidney Corp. (NASDAQ:PROK) Director Buys $54,735,339.78 in StockJune 14, 2024 | marketbeat.comProKidney Corp. (NASDAQ:PROK) Director Purchases $54,735,339.78 in StockProKidney Corp. (NASDAQ:PROK - Get Free Report) Director Pablo G. Legorreta acquired 22,617,909 shares of the stock in a transaction on Thursday, June 13th. The shares were bought at an average price of $2.42 per share, for a total transaction of $54,735,339.78. Following the purchase, the director now owns 22,617,909 shares in the company, valued at $54,735,339.78. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.June 13, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Shares Down 5% ProKidney (NASDAQ:PROK) Stock Price Down 5%June 12, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Sees Unusually-High Trading VolumeProKidney (NASDAQ:PROK) Sees Unusually-High Trading VolumeJune 11, 2024 | globenewswire.comProKidney Announces Pricing of its Upsized $130 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingJune 10, 2024 | globenewswire.comProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct OfferingJune 10, 2024 | marketbeat.comProKidney (NASDAQ:PROK) PT Lowered to $6.00Jefferies Financial Group decreased their price objective on ProKidney from $15.00 to $6.00 and set a "buy" rating for the company in a report on Monday.June 10, 2024 | globenewswire.comProKidney Announces Positive Interim REGEN-007 Phase 2 Trial Data and Provides Clinical and Operational UpdatesJune 7, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Down 9.2%ProKidney (NASDAQ:PROK) Stock Price Down 9.2%June 3, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Up 10.6%ProKidney (NASDAQ:PROK) Stock Price Up 10.6%May 31, 2024 | marketbeat.comProKidney (NASDAQ:PROK) Trading Down 6.2%ProKidney (NASDAQ:PROK) Stock Price Down 6.2%May 29, 2024 | marketbeat.comBank of America Raises ProKidney (NASDAQ:PROK) Price Target to $4.00Bank of America raised their target price on shares of ProKidney from $3.00 to $4.00 and gave the company a "neutral" rating in a report on Wednesday.May 29, 2024 | globenewswire.comProKidney to Participate in the Jefferies Global Healthcare ConferenceMay 29, 2024 | markets.businessinsider.comBuy Rating Affirmed for ProKidney on Rilparencel’s Promising Efficacy in CKD TreatmentMay 23, 2024 | insidertrades.comInsider Selling: ProKidney Corp. (NASDAQ:PROK) Insider Sells 17,238 Shares of StockMay 23, 2024 | seekingalpha.comProKidney: Date Due In Several Days May Enhance Bull Thesis, But I'm Skeptical Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Why billionaires are wiring money to abandoned towns (Ad)A new force is brewing in these forgotten towns that could soon turn Appalachia into one of America’s most valuable economic hubs – the beating heart of a new multi-billion-dollar revolution. Click here for my exclusive video PROK Media Mentions By Week PROK Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PROK News Sentiment▼0.270.55▲Average Medical News Sentiment PROK News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PROK Articles This Week▼122▲PROK Articles Average Week Get ProKidney News Delivered to You Automatically Sign up to receive the latest news and ratings for PROK and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: AKLI News VRNA News NTLA News BHC News VERA News MIRM News HRMY News ZLAB News GLPG News KNSA News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PROK) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProKidney Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProKidney With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.